Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$53.26
Market cap
$674.79M
P/E Ratio
35.99
Dividend/share
$0.78
EPS
$1.48
Enterprise value
$626.63M
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system
Highlights
The company's debt has shrunk by 83% YoY and by 81% QoQ
Iradimed's EPS has increased by 28% YoY and by 4.2% QoQ
IRMD's price to earnings (P/E) is 45% lower than its 5-year quarterly average of 64.9 but 9% higher than its last 4 quarters average of 32.5
Key stats
What are the main financial stats of IRMD
Market
Valuations
Earnings
Shares outstanding
12.67M
Market cap
$674.79M
Enterprise value
$626.63M
Price to earnings (P/E)
35.99
Price to book (P/B)
8.47
Price to sales (P/S)
9.71
EV/EBIT
26.55
EV/EBITDA
25.66
EV/Sales
9.02
Revenue
$69.48M
EBIT
$23.6M
EBITDA
$24.42M
Free cash flow
$13.01M
Per share
Balance sheet
Liquidity
EPS
$1.48
Free cash flow per share
$1.03
Book value per share
$6.29
Revenue per share
$5.49
TBVPS
$6.89
Total assets
$89.95M
Total liabilities
$10.28M
Debt
$371,849
Equity
$79.67M
Working capital
$66.12M
Debt to equity
0
Current ratio
9.87
Quick ratio
8.11
Net debt/EBITDA
-1.97
Margins
Efficiency
Dividend
EBITDA margin
35.1%
Gross margin
77.2%
Net margin
26.8%
Operating margin
30.9%
Return on assets
20.9%
Return on equity
24.7%
Return on invested capital
76%
Return on capital employed
28.6%
Return on sales
34%
Dividend yield
1.46%
DPS
$0.78
Payout ratio
52.7%
IRMD stock price
How has the Iradimed stock price performed over time
Intraday
1.35%
1 week
5.49%
1 month
5.91%
1 year
32.82%
YTD
12.2%
QTD
5.91%
Financial performance
How have Iradimed's revenue and profit performed over time
Revenue
$69.48M
Gross profit
$53.65M
Operating income
$21.44M
Net income
$18.64M
Gross margin
77.2%
Net margin
26.8%
Iradimed's net income has increased by 27% YoY and by 4% from the previous quarter
The company's operating income rose by 24% YoY and by 3.2% QoQ
The gross profit is up by 17% YoY and by 3.5% QoQ
The company's revenue rose by 16% YoY and by 2.7% QoQ
Growth
What is Iradimed's growth rate over time
Valuation
What is Iradimed stock price valuation
P/E
35.99
P/B
8.47
P/S
9.71
EV/EBIT
26.55
EV/EBITDA
25.66
EV/Sales
9.02
IRMD's price to earnings (P/E) is 45% lower than its 5-year quarterly average of 64.9 but 9% higher than its last 4 quarters average of 32.5
Iradimed's EPS has increased by 28% YoY and by 4.2% QoQ
The price to book (P/B) is 33% higher than the 5-year quarterly average of 6.3 and 11% higher than the last 4 quarters average of 7.5
Iradimed's equity has increased by 15% YoY and by 4.7% QoQ
The company's revenue rose by 16% YoY and by 2.7% QoQ
The price to sales (P/S) is 11% higher than the last 4 quarters average of 8.6 and 6% higher than the 5-year quarterly average of 9.0
Efficiency
How efficient is Iradimed business performance
Iradimed's return on equity has increased by 17% YoY
The company's return on assets rose by 15% YoY
Iradimed's return on sales has increased by 10% YoY
Iradimed's return on invested capital has decreased by 6% YoY
Dividends
What is IRMD's dividend history
DPS
$0.78
Dividend yield
1.46%
Payout ratio
52.7%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Iradimed financials performed over time
Iradimed's total liabilities has decreased by 17% YoY and by 14% QoQ
The current ratio is up by 13% year-on-year and by 4.6% since the previous quarter
The company's debt is 100% lower than its equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The company's debt has shrunk by 83% YoY and by 81% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.